Benjamin Edwards Inc. Invests $279,000 in Walgreens Boots Alliance, Inc. (NASDAQ:WBA)

Benjamin Edwards Inc. bought a new position in Walgreens Boots Alliance, Inc. (NASDAQ:WBAFree Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 31,110 shares of the pharmacy operator’s stock, valued at approximately $279,000.

A number of other large investors have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its holdings in Walgreens Boots Alliance by 43.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,969,188 shares of the pharmacy operator’s stock valued at $98,284,000 after purchasing an additional 3,329,857 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Walgreens Boots Alliance by 12.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,594,475 shares of the pharmacy operator’s stock valued at $68,046,000 after purchasing an additional 817,762 shares during the last quarter. Thompson Siegel & Walmsley LLC grew its holdings in Walgreens Boots Alliance by 15.5% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 6,955,880 shares of the pharmacy operator’s stock valued at $62,325,000 after purchasing an additional 934,754 shares during the last quarter. FMR LLC grew its holdings in Walgreens Boots Alliance by 2.5% during the 3rd quarter. FMR LLC now owns 3,258,919 shares of the pharmacy operator’s stock valued at $29,200,000 after purchasing an additional 80,525 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Walgreens Boots Alliance by 6.1% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,718,659 shares of the pharmacy operator’s stock valued at $32,882,000 after purchasing an additional 156,484 shares during the last quarter. 58.59% of the stock is currently owned by institutional investors.

Walgreens Boots Alliance Price Performance

Shares of WBA opened at $8.85 on Tuesday. Walgreens Boots Alliance, Inc. has a fifty-two week low of $8.08 and a fifty-two week high of $27.05. The company has a 50 day moving average price of $9.15 and a 200-day moving average price of $10.84. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.37 and a current ratio of 0.68. The stock has a market capitalization of $7.65 billion, a PE ratio of -0.88, a PEG ratio of 1.12 and a beta of 0.66.

Walgreens Boots Alliance (NASDAQ:WBAGet Free Report) last posted its earnings results on Tuesday, October 15th. The pharmacy operator reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.03. Walgreens Boots Alliance had a negative net margin of 5.85% and a positive return on equity of 14.23%. The company had revenue of $37.50 billion during the quarter, compared to analysts’ expectations of $35.75 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. Walgreens Boots Alliance’s revenue for the quarter was up 5.9% compared to the same quarter last year. Equities analysts predict that Walgreens Boots Alliance, Inc. will post 1.53 earnings per share for the current fiscal year.

Walgreens Boots Alliance Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Monday, November 18th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $1.00 dividend on an annualized basis and a yield of 11.30%. Walgreens Boots Alliance’s payout ratio is -9.99%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on WBA shares. JPMorgan Chase & Co. cut their price target on shares of Walgreens Boots Alliance from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, August 30th. TD Cowen dropped their target price on shares of Walgreens Boots Alliance from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, October 22nd. Barclays upped their target price on shares of Walgreens Boots Alliance from $7.00 to $8.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 16th. Morgan Stanley dropped their target price on shares of Walgreens Boots Alliance from $9.00 to $7.00 and set an “underweight” rating on the stock in a research note on Friday, October 11th. Finally, UBS Group upped their target price on shares of Walgreens Boots Alliance from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.58.

View Our Latest Stock Analysis on WBA

Walgreens Boots Alliance Profile

(Free Report)

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.

Read More

Want to see what other hedge funds are holding WBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Walgreens Boots Alliance, Inc. (NASDAQ:WBAFree Report).

Institutional Ownership by Quarter for Walgreens Boots Alliance (NASDAQ:WBA)

Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.